Sionna Therapeutics (SION) Capital Expenditures (2024 - 2025)
Sionna Therapeutics (SION) reported Capital Expenditures of $204000.0 for Q4 2025, up 655.56% on a YoY basis from $27000.0 in Q4 2024, and up 134.48% sequentially from $87000.0 in Q3 2025.
Sionna Therapeutics (SION) Capital Expenditures (2024 - 2025) Analysis & Trends
Sionna Therapeutics (SION) has 2 years of Capital Expenditures data on file, last reported at $204000.0 in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures rose 655.56% year-over-year to $204000.0; the trailing twelve-month figure through Mar 2026 stood at $291000.0 (up 157.52% YoY), and the FY2025 full-year result was $377000.0, up 1296.3% from the prior year.
- Capital Expenditures advanced to $204000.0 in Q4 2025, from $87000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $204000.0 in Q4 2025 to a low of $27000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Sionna Therapeutics | 1.98 Bn | 1.98 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 204,000.00 |
| Dec 31, 2025 | 204,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Sep 30, 2025 | 87,000.00 |
| Mar 31, 2025 | 86,000.00 |
| Mar 31, 2025 | 86,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |